利拉鲁肽3.0 mg在超重或肥胖且接受基础胰岛素治疗的2型糖尿病患者中的疗效与安全性:SCALE胰岛素随机对照试验
SCALE胰岛素研究是一项为期56周、随机、双盲、安慰剂对照、多国多中心试验,纳入超重或肥胖且接受基础胰岛素治疗的2型糖尿病患者。利拉鲁肽3.0 mg联合强化行为治疗较安慰剂显著降低体重(估计治疗差异-4.3% [95% CI -5.5; -3.2];P < 0.0001),更多患者达到≥5%体重减轻(51.8% vs 24.0%;OR 3.41 [95% CI 2.19; 5.31];P < 0.0001),并改善血糖控制且低血糖事件未增加。
要点
- 利拉鲁肽3.0 mg联合强化行为治疗56周平均体重变化-5.8%,安慰剂组-1.5%。
- 利拉鲁肽3.0 mg组51.8%达到≥5%体重减轻,安慰剂组24.0%。
- 利拉鲁肽3.0 mg显著降低HbA1c和日间平均血糖,减少胰岛素需求,低血糖事件少于安慰剂。
核心结论
- 在超重或肥胖且接受胰岛素治疗的2型糖尿病患者中,利拉鲁肽3.0 mg作为强化行为治疗的辅助治疗,在体重减轻和改善血糖控制方面优于安慰剂,尽管基础胰岛素剂量更低且低血糖事件未增加。
研究设计与样本
- SCALE胰岛素研究是一项为期56周、随机、双盲、安慰剂对照、多国多中心试验,纳入超重或肥胖且接受基础胰岛素和≤2种口服降糖药治疗的2型糖尿病患者,随机分配至利拉鲁肽3.0 mg(n=198)或安慰剂(n=198),均联合强化行为治疗。
主要发现
- 56周时,利拉鲁肽3.0 mg组平均体重变化为-5.8%,安慰剂组为-1.5%(估计治疗差异-4.3% [95% CI -5.5; -3.2];P < 0.0001)。
- 利拉鲁肽3.0 mg组51.8%的个体达到≥5%体重减轻,安慰剂组为24.0%(OR 3.41 [95% CI 2.19; 5.31];P < 0.0001)。
- 利拉鲁肽3.0 mg与安慰剂相比,平均HbA1c和日间平均血糖值显著降低更多,且胰岛素需求更少,尽管有治疗至血糖目标的方案。
- 安慰剂组观察到的低血糖事件多于利拉鲁肽3.0 mg组。
- 未观察到新的安全性或耐受性问题。
临床怎么用
- 原文结论认为,在超重或肥胖且接受胰岛素治疗的2型糖尿病患者中,利拉鲁肽3.0 mg作为强化行为治疗的辅助治疗,在体重减轻和改善血糖控制方面优于安慰剂。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Most individuals with type 2 diabetes also have obesity, and treatment with some diabetes medications, including insulin, can cause further weight gain. No approved chronic weight management medications have been prospectively investigated in individuals with overweight or obesity and insulin-treated type 2 diabetes. The primary objective of this study was to assess the effect of liraglutide 3.0 mg versus placebo on weight loss in this population. RESEARCH DESIGN AND METHODS: Satiety and Clinical Adiposity-Liraglutide Evidence (SCALE) Insulin was a 56-week, randomized, double-blind, placebo-controlled, multinational, multicenter trial in individuals with overweight or obesity and type 2 diabetes treated with basal insulin and ≤2 oral antidiabetic drugs. RESULTS: Individuals were randomized to liraglutide 3.0 mg (n = 198) or placebo (n = 198), combined with intensive behavioral therapy (IBT). At 56 weeks, mean weight change was -5.8% for liraglutide 3.0 mg versus -1.5% with placebo (estimated treatment difference -4.3% [95% CI -5.5; -3.2]; P < 0.0001). With liraglutide 3.0 mg, 51.8% of individuals achieved ≥5% weight loss versus 24.0% with placebo (odds ratio 3.41 [95% CI 2.19; 5.31]; P < 0.0001). Liraglutide 3.0 mg was associated with significantly greater reductions in mean HbA1c and mean daytime glucose values and less need for insulin versus placebo, despite a treat-to-glycemic-target protocol. More hypoglycemic events were observed with placebo than liraglutide 3.0 mg. No new safety or tolerability issues were observed. CONCLUSIONS: In individuals with overweight or obesity and insulin-treated type 2 diabetes, liraglutide 3.0 mg as an adjunct to IBT was superior to placebo regarding weight loss and improved glycemic control despite lower doses of basal insulin and without increases in hypoglycemic events.
引用
- Garvey WT, Birkenfeld AL, Dicker D, et al. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial. Diabetes Care. 2020. PMID: 32139381. doi:10.2337/dc19-1745
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。